BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-504@pharmaconomics
DTSTAMP:20260707T020343Z
DTSTART;VALUE=DATE:20260201
DTEND;VALUE=DATE:20260202
SUMMARY:TECX AdCom — TX2100
DESCRIPTION:An FDA advisory committee reviews TX2100 for Hereditary Hemorrhagic Telangiectasia (HHT) around Feb 1\, 2026. The panel's public vote often front-runs the agency's final verdict — and the share price.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1681087/000119312526076843/tecx-ex99_1.htm\n\nTrack it: https://pharmaconomics.com/e/504
URL:https://pharmaconomics.com/e/504
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:TECX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR